Abstract | OBJECTIVE: METHODS: The clinical data of 53 advanced stage BAC patients treated from Jan. 1999 to Dec. 2004 was collected and reviewed. Most of the patients received more than 2 cycles of the combined chemotherapy with platinum-based regimen. RESULTS: Of these 53 eligible patients in this series, 34 (64.2%) were women, 42 (79.2%) never smoked any cigarette, 29 (54.7%) originated from the right lung, and 12 patients (22.6%) showed bilateral multi-lobular or multi-central lesions or diffusive pulmonary involvement. The objective response rate was 17.0% (2 complete response, 7 partial response). 30 (56.6%) patients demonstrated stable disease and 14 (26.4%) patients showed progression of the disease. The median progression-free and overall survivals were 6.1 and 16.0 months, respectively. The 1-year survival rate was 71.7%. Grade 3 or severer toxicities included neutropenia (34.0%), thrombocytopenia (15.1%), anemia (22.6%), nausea and vomiting (39.6%), alopecia (30.2%), constipation (17.0%) and peripheral neurotoxicity (13.2%). CONCLUSION:
|
Authors | Yong Li, Xiang-ru Zhang, Yan Sun |
Journal | Zhonghua zhong liu za zhi [Chinese journal of oncology]
(Zhonghua Zhong Liu Za Zhi)
Vol. 29
Issue 4
Pg. 298-301
(Apr 2007)
ISSN: 0253-3766 [Print] China |
PMID | 17760260
(Publication Type: Journal Article)
|
Chemical References |
- Deoxycytidine
- Vinblastine
- Cisplatin
- Vinorelbine
- Gemcitabine
|
Topics |
- Adenocarcinoma, Bronchiolo-Alveolar
(drug therapy, pathology)
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols
(adverse effects, therapeutic use)
- Cisplatin
(administration & dosage)
- Deoxycytidine
(administration & dosage, analogs & derivatives)
- Disease-Free Survival
- Female
- Follow-Up Studies
- Humans
- Lung Neoplasms
(drug therapy, pathology)
- Male
- Middle Aged
- Neoplasm Staging
- Neutropenia
(chemically induced)
- Remission Induction
- Retrospective Studies
- Sex Factors
- Smoking
- Vinblastine
(administration & dosage, analogs & derivatives)
- Vinorelbine
- Gemcitabine
|